HomeCompareSTCN vs PFE

STCN vs PFE: Dividend Comparison 2026

STCN yields 16.42% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STCN wins by $32.6K in total portfolio value
10 years
STCN
STCN
● Live price
16.42%
Share price
$12.18
Annual div
$2.00
5Y div CAGR
5.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$82.1K
Annual income
$10,418.27
Full STCN calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — STCN vs PFE

📍 STCN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTCNPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STCN + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STCN pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STCN
Annual income on $10K today (after 15% tax)
$1,395.73/yr
After 10yr DRIP, annual income (after tax)
$8,855.53/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $13,464.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STCN + PFE for your $10,000?

STCN: 50%PFE: 50%
100% PFE50/50100% STCN
Portfolio after 10yr
$65.8K
Annual income
$18,338.49/yr
Blended yield
27.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

STCN
No analyst data
Altman Z
1.6
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STCN buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTCNPFE
Forward yield16.42%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR5.7%13.2%
Portfolio after 10y$82.1K$49.6K
Annual income after 10y$10,418.27$26,258.71
Total dividends collected$50.3K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: STCN vs PFE ($10,000, DRIP)

YearSTCN PortfolioSTCN Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$12,436$1,735.63$9,153$693.39+$3.3KSTCN
2$15,438$2,132.15$8,593$849.25+$6.8KSTCN
3$19,134$2,614.80$8,336$1,066.78+$10.8KSTCN
4$23,674$3,201.34$8,437$1,384.80+$15.2KSTCN
5$29,245$3,912.93$9,013$1,875.40+$20.2KSTCN
6$36,067$4,774.85$10,306$2,680.72+$25.8KSTCN
7$44,408$5,817.14$12,820$4,101.38+$31.6KSTCN
8$54,593$7,075.56$17,673$6,826.70+$36.9KSTCN
9$67,007$8,592.52$27,543$12,591.86+$39.5KSTCN
10$82,115$10,418.27$49,560$26,258.71+$32.6KSTCN

STCN vs PFE: Complete Analysis 2026

STCNStock

Steel Connect, Inc., together with its subsidiaries, provides direct marketing and supply chain services in the United States, Mainland China, and internationally. The company provides data-driven marketing solutions, including strategy, data and analytics, response analysis, creative services, lithographic and digital printing, envelope printing and converting, component manufacturing, promotional cards, data processing and hygiene, content and asset management, personalization, lettershop and bindery, and postal optimization and omnichannel marketing campaigns, as well as provides business continuity and disaster recovery services. It also offers product configuration and packaging, kitting, and assembly of components and parts into finished goods; and value-added processes, such as product testing, radio frequency identification tagging, product or service activation, language settings, personalization and engraving, multi-channel packaging, and packaging design services. In addition, the company provides fulfillment services comprising order management, pick, pack and ship, retail compliance, and demand planning services; and reverse logistics services that simplifies the returns process for retailers and manufacturers, as well as operates a cloud-based e-commerce platform. Steel Connect, Inc. offers its supply chain services to customers in the consumer electronics, communications, computing, medical devices, software, and retail markets. The company was formerly known as ModusLink Global Solutions, Inc. and changed its name to Steel Connect, Inc. in February 2018. Steel Connect, Inc. was incorporated in 1986 and is headquartered in Smyrna, Tennessee.

Full STCN Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this STCN vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STCN vs SCHDSTCN vs JEPISTCN vs OSTCN vs KOSTCN vs MAINSTCN vs JNJSTCN vs MRKSTCN vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.